Kazia Therapeutics Ltd ADR (KZIA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol KZIA
- Company Kazia Therapeutics Ltd ADR
- Price $13.77
- Changes Percentage 1.4
- Change 0.19
- Day Low $13
- Day High $14.42
- Year High $17.4
- Year Low $4.86
- Market Cap $21,713,298
- Price Avg 50 EMA (D) $13.42
- Price Avg 200 EMA (D) $10.22
- Exchange NASDAQ
- Volume 148,969
- Average Volume 190,956
- Open $13.7
- Previous Close $13.58
- EPS -4.76
- PE -2.81
- Earnings Announcement 2026-09-04 12:00:00
- Shares Outstanding $1,619,791
Company brief: KAZIA THERAPEUTICS LTD ADR (KZIA )
- Healthcare
- Biotechnology
- Dr. John Edwin Friend II, M.D.
- https://www.kaziatherapeutics.com
- AU
- N/A
- 01-06-1999
- US48669G1058
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.